What Should Beta Bionics, Inc. Investors Know After 37% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

Lawsuit alleges Beta Bionics, Inc. made misleading statements to investors from July 30, 2025 to February 24, 2026; lead plaintiff motions are due November 3, 2026

LOS ANGELES, Oct. 26, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors who acquired the Company's securities from July 30, 2025 to February 24, 2026. Filed on September 4, 2026, the case is Holtzman v. Beta Bionics, Inc., et al., U.S. District Court for the Central District of California, Case No. 8:26-cv-02612.

If you lost money on Beta Bionics, Inc. securities, submit your Beta Bionics, Inc. loss information by November 3, 2026 to learn about participating in the lawsuit.

Beta Bionics, Inc. class action timeline

• Class period begins: July 30, 2025
• Class period ends: February 24, 2026
• Complaint filed: September 4, 2026
• Lead plaintiff motion deadline: November 3, 2026

What happened?

On January 8, 2026, Beta Bionics released preliminary fourth quarter 2025 financial results, revealing that new patient starts would be "up at least 36%" — lower than analysts had estimated for the quarter.

On this news, Beta Bionics' stock price fell $11.85, or 37%, to close at $20.15 per share on January 9, 2026, thereby injuring investors.

What is the Beta Bionics, Inc. lawsuit about?

The Beta Bionics, Inc. securities lawsuit alleges that, between July 30, 2025 and February 24, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Beta Bionics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Defendants omitted mention of the FDA Form 483 and iLet's underlying safety issues, including that the Form 483 identified over 18,000 complaints including numerous life-threatening hypoglycemic events that the Company had "failed to investigate," or even report to the FDA, with no justification; (2) the Company's statements assuring investors that its remediation efforts were advanced and the FDA's issues were "very benign," failed to accurately describe the scope and severity of the FDA's observations which made remediation much more complex and extensive than Defendants indicated to investors; (3) that the Company "could have opened a CAPA and did not" was misleading where the FDA had in fact concluded that Beta Bionics had, without justification, failed to investigate clearly serious, life-threatening customer reports; and (4) as a result, defendants' positive statements about Beta Bionics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

"According to the complaint filed against Beta Bionics, Inc., the Company, among other things, did not disclose that Defendants omitted mention of the FDA Form 483 and iLet's underlying safety issues, including that the Form 483 identified over 18,000 complaints including numerous life-threatening hypoglycemic events that the Company had "failed to investigate," or even report to the FDA, with no justification. The November 3, 2026 deadline is a key date for Beta Bionics, Inc. investors who want a voice in how this case moves forward," said Frank R. Cruz of The Law Offices of Frank R. Cruz.

What should Beta Bionics, Inc. investors do now?

The Law Offices of Frank R. Cruz can help Beta Bionics, Inc. investors evaluate potential claims to recover their losses.

Investors who want to serve as lead plaintiff in the Beta Bionics, Inc. class action must file a motion with the Court by November 3, 2026. For more information, visit the Beta Bionics, Inc. case page, email [email protected], or call 310-914-5007.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

Investors may retain counsel of their choice. Beta Bionics, Inc. investors who bought during the class period may also take no action and remain absent class members. No class has been certified yet in the Beta Bionics, Inc. case.

Questions and answers about the Beta Bionics, Inc. lawsuit

Who is eligible? Investors who bought Beta Bionics, Inc. securities between July 30, 2025 and February 24, 2026 and lost money may be class members, and may seek lead plaintiff appointment by November 3, 2026.

What does a lead plaintiff do? The lead plaintiff is appointed by the court to represent all class members and direct the Beta Bionics, Inc. class action.

Must I be lead plaintiff to share in a recovery? No, Beta Bionics, Inc. investors can take no action and remain absent class members.

How are attorneys' fees handled? The Law Offices of Frank R. Cruz works on contingency, so Beta Bionics, Inc. investors pay no attorneys' fees up front. Any attorneys' fees and litigation expenses come only from a recovery, if there is one, and require court approval.

About The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz investigates and prosecutes securities fraud and corporate malfeasance class actions. With nearly 20 years of litigation experience, the firm focuses on complex securities class actions and gives each client personal, one-on-one attention throughout the legal process.

Prior results do not guarantee a similar outcome.

Related links

• Beta Bionics, Inc. case page, The Law Offices of Frank R. Cruz
• Complaint: Holtzman v. Beta Bionics, Inc., et al., U.S. District Court for the Central District of California
• press release
• Beta Bionics, Inc. SEC filings index, EDGAR
• The Law Offices of Frank R. Cruz

Follow The Law Offices of Frank R. Cruz for updates on Twitter: twitter.com/FRC_LAW

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE The Law Offices of Frank R. Cruz, Los Angeles